Bcl-2 has been found to be overexpressed in CLL cells, where it mediates tumor cell survival and has been associated with resistance to therapy (Billard, 2012; Shehata et al., 2010). This evidence concerns the gene BCL2 and B-cell chronic lymphocytic leukemia.